FDA Approves Label Update for Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)

U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of Brukinsa versus Imbruvica® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news